Navigation Links
New Ovarian Cancer Drug Trial Under Way
Date:9/7/2007

Phenoxodiol could help women resistant to other medicines

FRIDAY, Sept. 7 (HealthDay News) -- Ovarian cancer patients whose cancer has become resistant to traditional chemotherapy can now log-on to a new Web site to learn about a trial of a new drug, phenoxodiol.

In previous studies, phenoxodiol has shown some success in helping traditional chemotherapies continue to fight cancer cells.

The Phase III study of phenoxodiol will take place at 30 sites in the United States, 26 sites in Europe and at least four sites in Australia.

The goal of the Web site, www.OVATUREtrial.com, is to inform ovarian cancer patients about the Ovarian Tumor Response (OVATURE) trial, which is actively recruiting patients. Women suffering with ovarian cancer can learn about the study, the medication and locations for them to participate.

The trial is studying the safety and effectiveness of the drug phenoxodiol when combined with weekly doses of the chemotherapy drug carboplatin. Phenoxodiol is believed to help chemotherapy drugs kill chemoresistant cancer cells by removing factors in the cells that block the killing action of chemotherapy. Phenoxodiol has not yet been approved for use by the U.S. Food and Drug Administration.

Women who enter the trial will be assigned to one of two courses of treatment. The first will receive weekly carboplatin and phenoxodiol. Patients in the other course will receive carboplatin and a placebo weekly. Patients and their doctors will not know which course of treatment they have been given.

Receiving carboplatin weekly instead of every two or three weeks has been shown to provide tumor response in some patients with recurrent ovarian cancer. The study will expand understanding of the safety and effectiveness of both phenoxodiol and weekly carboplatin.

Phenoxodiol has been shown to reverse resistance to standard chemotherapies in lab animals. In a prior Phase II clinical trial, the drug showed some success in reversing tumor progression when it was tested in combination with cisplatin or paclitaxel.

Ovarian cancer occurs in one out of every 69 women and is the fifth leading cause of cancer death in women, according to the Ovarian Cancer National Alliance. It can be treated if diagnosed early, but most ovarian cancers are caught at later stages. When diagnosed in an advanced stage, women have a 30 percent chance of surviving five years.

More information

To learn more about ovarian cancer, visit the Ovarian Cancer National Alliance.



-- Madeline Vann



SOURCE: OVATURE, press release, Aug. 30, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Progestin protects against ovarian cancer
3. Inherited gene important in ovarian cancer
4. Blood test may identify ovarian cancer
5. Exercise lowers Risk of Ovarian Cancer
6. Screening device for ovarian cancer
7. Ethnic discrepancy in ovarian cancer
8. Associated scan for detecting ovarian cancer spread
9. Gene Mutation Causes Ovarian Failure
10. Ovarian Cancer Screening Questioned
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been named ... by the American Institute of Architects and the Academy of Architecture for Health. The ... and Harrell Architects, opened to patients in October of 2014. , ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
(Date:5/5/2016)... ... May 05, 2016 , ... In order to increase ... patterns, Amerec, a Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ ... interface of the app, developed for both smartphones and personal computers perfectly emulates ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... on the eve of National Nurses Week (May 6-12). Currently, HireNurses is ... With their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically ...
(Date:5/5/2016)... ... , ... Chronic stress can have a silent, yet dangerous, impact on men’s ... and increase inflammation, both of which raise the risk of heart attack and even ... at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other issues that ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016   ... the importance of extending care beyond the implant at ... Sessions, May 4-7 in San Francisco ... with continually delivering the highest quality of patient care ... patients are cared for each and every tomorrow," said ...
(Date:5/3/2016)... , May 3, 2016 ... pay $55 million to a woman who says its ... court awarded Gloria Ristesund $5 million in ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... accusations against the company. In February, the same court ...
(Date:5/3/2016)... TUSTIN, Calif. , May 3, 2016 /PRNewswire/ ... science teaching tool that shows how a cleanroom ... for classroom discussions about science and technology. ... Manager said, "As a technology company, SSF enthusiastically ... program to help educators foster the next generation ...
Breaking Medicine Technology: